Drug Profile
Recombinant factor VIII - mAbxience
Latest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator mAbxience
- Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
- Mechanism of Action Factor VIII stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Haemophilia A
Most Recent Events
- 13 Sep 2023 Discontinued - Preclinical for Haemophilia A in Spain (Parenteral) - (mAbxience pipeline, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Haemophilia-A in Spain (Parenteral)
- 02 Aug 2016 Preclinical trials in Haemophilia A in Spain (Parenteral)